Citation: Ar. Nissenson, Daily hemodialysis: Challenges and opportunities in the delivery and financing of end-stage renal disease patient care, ADV RENAL R, 8(4), 2001, pp. 286-292
Authors:
Nissenson, AR
Collins, AJ
Hurley, J
Petersen, H
Pereira, BJG
Steinberg, EP
Citation: Ar. Nissenson et al., Opportunities for improving the care of patients with chronic renal insufficiency: Current practice patterns, J AM S NEPH, 12(8), 2001, pp. 1713-1720
Citation: Ar. Nissenson, Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease, AM J KIDNEY, 38(6), 2001, pp. 1390-1397
Authors:
Nissenson, AR
Pereira, BJG
Collins, AJ
Steinberg, EP
Citation: Ar. Nissenson et al., Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization, AM J KIDNEY, 37(6), 2001, pp. 1177-1183
Authors:
Nissenson, AR
Collins, AJ
Dickmeyer, J
Litchfield, T
Mattern, W
McMahill, CN
Muhlbaier, L
Nielsen, J
Owen, WF
Pereira, BJG
Steinman, TI
Szczech, L
Citation: Ar. Nissenson et al., Evaluation of disease-state management of dialysis patients, AM J KIDNEY, 37(5), 2001, pp. 938-944
Citation: Ar. Nissenson et Ra. Rettig, Medicare's end-stage renal disease program: Current status and future prospects, HEAL AFFAIR, 18(1), 1999, pp. 161-179
Authors:
Nissenson, AR
Lindsay, RM
Swan, S
Seligman, P
Strobos, J
Citation: Ar. Nissenson et al., Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial, AM J KIDNEY, 33(3), 1999, pp. 471-482
Citation: Ar. Nissenson et Ra. Rettig, Medicare's end-stage renal disease program: current status and future prospects, NEFROLOGIA, 19(3), 1999, pp. 210
Citation: Ar. Nissenson et al., Effects of normal as compared with low hematocrit values in patients with cardiac disease undergoing hemodialysis and receiving epoetin - Reply, N ENG J MED, 339(27), 1998, pp. 2023-2024